Precision Prevention: UK Government's Role in Unlocking Biology-Based Cancer Prevention Research

Key Takeaways

• Currently, 40% of cancers are preventable via known risk factors; precision prevention could increase this proportion by targeting the biological changes that drive cancer.
• The UK Government must prioritise precision prevention within the Life Sciences Sector Plan delivery and secure coordinated, long-term funding through UKRI and NIHR.
• Critical barriers include insufficient researcher capacity, a lack of targeted training programmes, and a regulatory environment not yet adapted for precision prevention trials.
• Strategic investment in this emerging field offers a clear economic opportunity for the UK to attract pharmaceutical investment and establish global leadership.

What is Precision Prevention and Why Does It Matter Now?

This 28-page policy report from Cancer Research UK, published in June 2026, outlines the transformative potential of precision prevention research. While reducing exposure to risk factors like tobacco and obesity remains essential, the report focuses on the additional impact of biology-based approaches. With the burden of cancer and other long-term conditions growing, and the UK Government’s ambition to shift ‘from sickness to prevention’ as outlined in the 10 Year Health Plan for England, the timing is critical.

How Can the UK Government Unlock This Opportunity?

The report identifies three key areas for government action. First, precision prevention research must be explicitly prioritised and supported through coordinated, long-term funding from UKRI and NIHR. Second, targeted training and capacity-building interventions are needed to address the researcher capacity gap, particularly at the postdoctoral stage and within clinical academic programmes. Third, the Medicines and Healthcare products Regulatory Agency (MHRA) must work with NICE and the HRA to develop guidance that addresses the regulatory needs of precision prevention trials.

Why Should Pharma Teams Engage Now?

Precision prevention opens new R&D avenues for biology-based interventions. Government backing could de-risk investment, create collaborative infrastructure, and streamline regulatory pathways. The report notes that prevention research is already attracting interest from the pharmaceutical industry, and building a UK precision prevention research capability has the potential to attract significant commercial investment, driving positive economic impact such as new jobs. Pharma teams should engage early to help shape funding priorities and trial designs.

Frequently Asked Questions

Is precision medicine the future of healthcare?

Precision prevention is a rapidly developing area with the potential to transform prevention of long-term conditions. By targeting the biological changes that drive cancer rather than risk factors alone, it could significantly increase the proportion of cancers considered preventable, representing a major shift towards more proactive, biology-based healthcare.

Is the UK life sciences losing out on 15bn a year to overseas rivals?

While this specific figure is not cited in the report, the document makes a clear economic case for investment. It notes that the Industrial Strategy identified life sciences as one of the UK’s highest-potential sectors, and that building a precision prevention research capability could attract commercial investment to the UK, creating new jobs and driving positive economic impact at a crucial moment when global shifts in research funding have negatively impacted prevention research internationally.

What is the success rate of precision medicine?

The report does not provide a specific success rate for precision medicine. However, it states that Cancer Research UK’s strategic investment in precision prevention research, including through its Biology to Prevention Award, has increased research activity and sparked international interest, while also exposing significant barriers within the UK’s research environment that require government action to address.

Related coverage

• Global Health in the Age of AI